COMP <GO>
ADMA vs ABBV // RETURN ON INVESTED CAPITAL (ROIC)
ADMA Biologics Inc (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: ADMA 7
— ABBV 5
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: ADMA
LAST: $11.75 (+4.17%) • MKT CAP: $2.63B
roic
32.90%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
roic
29.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ADMA VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ADMA | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 57.40% | 70.20% | -12.80 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 32.90% | 29.00% | +3.90 | ADMA | /roic <GO> |
| EV/EBITDA & P/E Valuation | 12.4x | 33.3x | -20.90 | ADMA | /valuation <GO> |
| Free Cash Flow Yield | 1.06% | 3.47% | -2.41 | ABBV | /fcf-yield <GO> |
| Operating Margin | 37.50% | 24.60% | +12.90 | ADMA | /operating-margins <GO> |
| Net Profit Margin | 28.80% | 6.90% | +21.90 | ADMA | /net-margins <GO> |
| Revenue Growth (YoY) | 19.60% | 8.60% | +11.00 | ADMA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 12.98 | 5.33 | +7.65 | ADMA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 64.1 | 65.1 | -1.02 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 15.0x | 113.1x | -98.10 | ADMA | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.63B | $513.86B | -$511.23B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ADMA REV | ABBV REV | ADMA GROSS % | ABBV GROSS % | ADMA FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $510.2M | $61.16B | 57.4% | 70.2% | $27.8M | $17.82B |
| FY 2024 | $426.5M | $56.33B | 51.5% | 70.0% | $110.4M | $17.83B |
| FY 2023 | $258.2M | $54.32B | — | — | $8.8M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ADMA // BETA —
ABBV // BETA 1.15